Base de dados : MEDLINE
Pesquisa : D03.383.773.812.226 [Categoria DeCS]
Referências encontradas : 535 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 54 ir para página                         

  1 / 535 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28225296
[Au] Autor:Suzuki Y; Kamada N; Ohno H; Abe Y; Endo T; Kobayashi M
[Ad] Endereço:Central Research Laboratories, Kissei Pharmaceutical Co., Ltd, 4365-1 Kashiwabara, Hotaka, Azumino, Nagano, Japan.
[Ti] Título:Development and validation of an LC-MS/MS method for simultaneously determining doxapram and keto-doxapram in human serum.
[So] Source:Bioanalysis;9(6):503-515, 2017 Mar.
[Is] ISSN:1757-6199
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:AIM: Doxapram, a respiratory stimulant, is used to treat apnea. A reliable method of determining doxapram in blood is required for monitoring purposes. RESULTS: Doxapram, keto-doxapram (active metabolite) and propranolol (internal standard) were extracted from human serum by protein precipitation and plate filtration. Molecular ions were generated by electrospray ionization in positive ion mode, and the ions were analyzed using a triple-quadrupole mass spectrometer. The calibration curves were linear from 20 to 5000 ng/ml. The method was validated and the selectivity, reproducibility and stability met the acceptance criteria. CONCLUSION: An LC-MS/MS method was successfully developed for determining doxapram and keto-doxapram in human serum. The method can be used to monitor doxapram and keto-doxapram concentrations in blood.
[Mh] Termos MeSH primário: Cromatografia Líquida/métodos
Doxapram/análogos & derivados
Doxapram/sangue
Espectrometria de Massas em Tandem/métodos
[Mh] Termos MeSH secundário: Calibragem
Monitoramento de Medicamentos
Estabilidade de Medicamentos
Seres Humanos
Limite de Detecção
Propranolol/sangue
Padrões de Referência
Reprodutibilidade dos Testes
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
42595-88-0 (2-ketodoxapram); 94F3830Q73 (Doxapram); 9Y8NXQ24VQ (Propranolol)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170314
[Lr] Data última revisão:
170314
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170223
[St] Status:MEDLINE
[do] DOI:10.4155/bio-2016-0267


  2 / 535 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28130789
[Au] Autor:Flint R; Halbmeijer N; Meesters N; van Rosmalen J; Reiss I; van Dijk M; Simons S
[Ad] Endereço:Division of Neonatology, Department of Paediatrics, Erasmus University Medical Centre - Sophia Children's Hospital, Rotterdam, The Netherlands.
[Ti] Título:Retrospective study shows that doxapram therapy avoided the need for endotracheal intubation in most premature neonates.
[So] Source:Acta Paediatr;106(5):733-739, 2017 May.
[Is] ISSN:1651-2227
[Cp] País de publicação:Norway
[La] Idioma:eng
[Ab] Resumo:AIM: Using doxapram to treat neonates with apnoea of prematurity might avoid the need for endotracheal intubation and invasive ventilation. We studied whether doxapram prevented the need for intubation and identified the predictors of the success. METHODS: This was a retrospective study of preterm infants born from January 2006 to August 2014 who received oral or intravenous doxapram. Success was defined as no need for endotracheal intubation, due to apnoea, during doxapram therapy. Univariable and multivariable logistic regression analyses identified predictors of success during the first 48 hours of doxapram therapy. RESULTS: Data on 203 patients with a median gestational age of 26.1 (interquartile range 25.1-27.4) weeks were analysed. During the first 48 hours of doxapram therapy, 157 (77%) patients did not need endotracheal intubation and 127 (63%) patients were successfully treated over the entire treatment course. The median postnatal age at the start of doxapram therapy was 20 days (interquartile range 12-30). Postnatal age and a lower fraction of inspired oxygen at the start of doxapram therapy were significant predictors of success (odds ratio 0.964, 95% confidence interval 0.938-0.991, p = 0.001). CONCLUSION: Oral and intravenous doxapram effectively treated most cases of apnoea in preterm infants, avoiding the need for intubation.
[Mh] Termos MeSH primário: Apneia/tratamento farmacológico
Doxapram/uso terapêutico
Intubação Intratraqueal/estatística & dados numéricos
Fármacos do Sistema Respiratório/uso terapêutico
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Recém-Nascido
Recém-Nascido Prematuro
Masculino
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Respiratory System Agents); 94F3830Q73 (Doxapram)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170129
[St] Status:MEDLINE
[do] DOI:10.1111/apa.13761


  3 / 535 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27641247
[Au] Autor:Richards JR; Davis MT; Curry MR; Tsushima JH; McKinney HE
[Ad] Endereço:Department of Emergency Medicine, University of California Davis Medical Center, Sacramento, CA. Electronic address: jrrichards@ucdavis.edu.
[Ti] Título:Doxapram reversal of suspected gamma-hydroxybutyrate-induced coma.
[So] Source:Am J Emerg Med;35(3):517.e1-517.e3, 2017 03.
[Is] ISSN:1532-8171
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Coma/induzido quimicamente
Doxapram/administração & dosagem
Oxibato de Sódio/envenenamento
[Mh] Termos MeSH secundário: Adjuvantes Anestésicos/envenenamento
Administração Intravenosa
Idoso
Estimulantes do Sistema Nervoso Central/administração & dosagem
Estimulantes do Sistema Nervoso Central/uso terapêutico
Coma/tratamento farmacológico
Doxapram/uso terapêutico
Seres Humanos
Masculino
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adjuvants, Anesthesia); 0 (Central Nervous System Stimulants); 7G33012534 (Sodium Oxybate); 94F3830Q73 (Doxapram)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171003
[Lr] Data última revisão:
171003
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160920
[St] Status:MEDLINE


  4 / 535 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
[PMID]:27612991
[Au] Autor:Greze E; Benard M; Hamon I; Casper C; Haddad FE; Boutroy MJ; Hascoët JM
[Ad] Endereço:Neonatology, Maternite Regionale, EA3450 Université de Lorraine, 10 Rue du Docteur Heydenreich, 54035, Nancy, France.
[Ti] Título:Doxapram Dosing for Apnea of Prematurity Based on Postmenstrual Age and Gender: A Randomized Controlled Trial.
[So] Source:Paediatr Drugs;18(6):443-449, 2016 Dec.
[Is] ISSN:1179-2019
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Doxapram is used as a third-line treatment for apnea unresponsive to caffeine and continuous positive airway pressure (CPAP) in preterm infants. OBJECTIVES: The objectives of this study were to compare the effects of dosing adjusted for gender and postmenstrual age (PMA) (GrA) versus infants' weight alone (GrW) on doxapram plasma levels, clinical efficacy, and side effects. METHODS: This was a randomized, double-blind study, including premature infants for whom optimized caffeine and CPAP therapy for apnea of prematurity had failed. Failure was defined as the persistence of more than one significant apnea per hour over an 8-h period. Plasma levels of doxapram and ketodoxapram were measured with high-performance liquid chromatography (HPLC) 48 h after the onset of treatment. Dosing aimed to maintain the combined doxapram and ketodoxapram plasma level in the therapeutic range of 1.5-4 mg/l. Infants were followed-up for 4 days after the onset of treatment. RESULTS: A total of 85 infants were included: 46 in GrW (27.7 ± 1.9 weeks' gestational age [GA]), 39 in GrA (27.9 ± 1.4 weeks' GA); available plasma levels showed that 25 of 40 in the GrW group and 27 of 37 in the GrA group had levels within the therapeutic range (p = 0.344). Of note, plasma level variance was significantly higher in GrW for doxapram + ketodoxapram (1.87 vs. 0.89; p = 0.028). Clinical efficacy was better in the GrA group, with a reduction from 32 to 3 of 38 (76 %) infants with significant apnea versus 30 to 5 of 45 (56 %) in the GrW group (p < 0.001). No adverse effects were observed during the study. CONCLUSIONS: Taking gender and PMA into account for doxapram dosing did not significantly increase the number of infants with a plasma level in the therapeutic range. However, it improved plasma level stability and clinical efficacy without adverse effects. ClinicalTrials.gov number: NCT00389909.
[Mh] Termos MeSH primário: Apneia/tratamento farmacológico
Doxapram/administração & dosagem
Fármacos do Sistema Respiratório/administração & dosagem
[Mh] Termos MeSH secundário: Método Duplo-Cego
Feminino
Seres Humanos
Lactente
Recém-Nascido
Recém-Nascido Prematuro
Doenças do Prematuro/tratamento farmacológico
Masculino
Estudos Prospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Respiratory System Agents); 94F3830Q73 (Doxapram)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:171114
[Lr] Data última revisão:
171114
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160911
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE


  5 / 535 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27531058
[Au] Autor:Haw AJ; Meyer LC; Greer JJ; Fuller A
[Ad] Endereço:Brain Function Research Group, Faculty of Health Sciences, School of Physiology, University of the Witwatersrand, Parktown, South Africa.
[Ti] Título:Ampakine CX1942 attenuates opioid-induced respiratory depression and corrects the hypoxaemic effects of etorphine in immobilized goats (Capra hircus).
[So] Source:Vet Anaesth Analg;43(5):528-38, 2016 Sep.
[Is] ISSN:1467-2995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To determine whether CX1942 reverses respiratory depression in etorphine-immobilized goats, and to compare its effects with those of doxapram hydrochloride. STUDY DESIGN: A prospective, crossover experimental trial conducted at 1753 m.a.s.l. ANIMALS: Eight adult female Boer goats (Capra hircus) with a mean ± standard deviation mass of 27.1 ± 1.6 kg. METHODS: Following immobilization with 0.1 mg kg(-1) etorphine, goats received one of doxapram, CX1942 or sterile water intravenously, in random order in three trials. Respiratory rate, ventilation and tidal volume were measured continuously. Arterial blood samples for the determination of PaO2 , PaCO2 , pH and SaO2 were taken 2 minutes before and then at 5 minute intervals after drug administration for 25 minutes. RESULTS: Doxapram corrected etorphine-induced respiratory depression but also led to arousal and hyperventilation at 2 minutes after its administration, as indicated by the low PaCO2 (27.8 ± 4.5 mmHg) and ventilation of 5.32 ± 5.24 L minute(-1) above pre-immobilization values. CX1942 improved respiratory parameters and corrected etorphine's hypoxaemic effects more gradually than did doxapram, with a more sustained improvement in PaO2 and SaO2 in comparison with the control trial. CONCLUSIONS: CX1942 attenuated opioid-induced respiratory depression and corrected the hypoxaemic effects of etorphine in immobilized goats. CLINICAL RELEVANCE: Ampakines potentially offer advantages over doxapram, a conventional treatment, in reversing etorphine-induced respiratory depression without causing unwanted side effects, particularly arousal, in immobilized animals.
[Mh] Termos MeSH primário: Analgésicos Opioides/farmacologia
Etorfina/farmacologia
Hipóxia/induzido quimicamente
Receptores de AMPA/agonistas
Insuficiência Respiratória/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Doxapram/farmacologia
Feminino
Cabras
Hipóxia/tratamento farmacológico
Imobilização
Naltrexona/administração & dosagem
Antagonistas de Entorpecentes/farmacologia
Insuficiência Respiratória/induzido quimicamente
Fármacos do Sistema Respiratório/farmacologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics, Opioid); 0 (Narcotic Antagonists); 0 (Receptors, AMPA); 0 (Respiratory System Agents); 42M2Y6NU9O (Etorphine); 5S6W795CQM (Naltrexone); 94F3830Q73 (Doxapram)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170408
[Lr] Data última revisão:
170408
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160818
[St] Status:MEDLINE
[do] DOI:10.1111/vaa.12358


  6 / 535 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27233697
[Au] Autor:Richards JR; Laurin EG; Bretz SW; Traylor BR; Panacek EA
[Ad] Endereço:Department of Emergency Medicine, University of California Davis Medical Center, Sacramento, CA. Electronic address: jrrichards@ucdavis.edu.
[Ti] Título:Treatment of ethanol poisoning and associated hypoventilation with doxapram.
[So] Source:Am J Emerg Med;34(11):2253.e1-2253.e2, 2016 Nov.
[Is] ISSN:1532-8171
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Estimulantes do Sistema Nervoso Central/uso terapêutico
Doxapram/uso terapêutico
Etanol/envenenamento
Hipoventilação/induzido quimicamente
Fármacos do Sistema Respiratório/uso terapêutico
[Mh] Termos MeSH secundário: Serviço Hospitalar de Emergência
Seres Humanos
Hipoventilação/tratamento farmacológico
Masculino
Meia-Idade
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Central Nervous System Stimulants); 0 (Respiratory System Agents); 3K9958V90M (Ethanol); 94F3830Q73 (Doxapram)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160529
[St] Status:MEDLINE


  7 / 535 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27079743
[Au] Autor:Martinez JM; Gorman JM
[Ad] Endereço:New York University Medical Center, New York, NY, USA. Electronic address: jose.martinez@nyumc.org.
[Ti] Título:Authors' reply to comments on: Heart rate and respiratory response to doxapram in patients with panic disorder.
[So] Source:Psychiatry Res;239:364, 2016 05 30.
[Is] ISSN:1872-7123
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Mh] Termos MeSH primário: Doxapram/farmacologia
Transtorno de Pânico
[Mh] Termos MeSH secundário: Nível de Alerta/efeitos dos fármacos
Estimulantes do Sistema Nervoso Central/farmacologia
Frequência Cardíaca
Seres Humanos
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Central Nervous System Stimulants); 94F3830Q73 (Doxapram)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170201
[Lr] Data última revisão:
170201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160416
[St] Status:MEDLINE


  8 / 535 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27067323
[Au] Autor:Andersson JA; Fitts EC; Kirtley ML; Ponnusamy D; Peniche AG; Dann SM; Motin VL; Chauhan S; Rosenzweig JA; Sha J; Chopra AK
[Ad] Endereço:Institute for Translational Sciences, University of Texas Medical Branch (UTMB), Galveston, Texas, USA.
[Ti] Título:New Role for FDA-Approved Drugs in Combating Antibiotic-Resistant Bacteria.
[So] Source:Antimicrob Agents Chemother;60(6):3717-29, 2016 Jun.
[Is] ISSN:1098-6596
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Antibiotic resistance in medically relevant bacterial pathogens, coupled with a paucity of novel antimicrobial discoveries, represents a pressing global crisis. Traditional drug discovery is an inefficient and costly process; however, systematic screening of Food and Drug Administration (FDA)-approved therapeutics for other indications in humans offers a rapid alternative approach. In this study, we screened a library of 780 FDA-approved drugs to identify molecules that rendered RAW 264.7 murine macrophages resistant to cytotoxicity induced by the highly virulent Yersinia pestis CO92 strain. Of these compounds, we identified 94 not classified as antibiotics as being effective at preventing Y. pestis-induced cytotoxicity. A total of 17 prioritized drugs, based on efficacy in in vitro screens, were chosen for further evaluation in a murine model of pneumonic plague to delineate if in vitro efficacy could be translated in vivo Three drugs, doxapram (DXP), amoxapine (AXPN), and trifluoperazine (TFP), increased animal survivability despite not exhibiting any direct bacteriostatic or bactericidal effect on Y. pestis and having no modulating effect on crucial Y. pestis virulence factors. These findings suggested that DXP, AXPN, and TFP may modulate host cell pathways necessary for disease pathogenesis. Finally, to further assess the broad applicability of drugs identified from in vitro screens, the therapeutic potential of TFP, the most efficacious drug in vivo, was evaluated in murine models of Salmonella enterica serovar Typhimurium and Clostridium difficile infections. In both models, TFP treatment resulted in increased survivability of infected animals. Taken together, these results demonstrate the broad applicability and potential use of nonantibiotic FDA-approved drugs to combat respiratory and gastrointestinal bacterial pathogens.
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/farmacologia
Reposicionamento de Medicamentos
Enterocolite Pseudomembranosa/tratamento farmacológico
Peste/tratamento farmacológico
Infecções por Salmonella/tratamento farmacológico
Trifluoperazina/farmacologia
[Mh] Termos MeSH secundário: Amoxapina/farmacologia
Animais
Sobrevivência Celular/efeitos dos fármacos
Clostridium difficile/efeitos dos fármacos
Clostridium difficile/crescimento & desenvolvimento
Clostridium difficile/patogenicidade
Modelos Animais de Doenças
Doxapram/farmacologia
Esquema de Medicação
Enterocolite Pseudomembranosa/metabolismo
Enterocolite Pseudomembranosa/microbiologia
Enterocolite Pseudomembranosa/mortalidade
Feminino
Ensaios de Triagem em Larga Escala
Macrófagos/efeitos dos fármacos
Camundongos
Peste/metabolismo
Peste/microbiologia
Peste/mortalidade
Medicamentos sob Prescrição/farmacologia
Infecções por Salmonella/metabolismo
Infecções por Salmonella/microbiologia
Infecções por Salmonella/mortalidade
Salmonella typhimurium/efeitos dos fármacos
Salmonella typhimurium/crescimento & desenvolvimento
Salmonella typhimurium/patogenicidade
Bibliotecas de Moléculas Pequenas/farmacologia
Análise de Sobrevida
Yersinia pestis/efeitos dos fármacos
Yersinia pestis/crescimento & desenvolvimento
Yersinia pestis/patogenicidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Prescription Drugs); 0 (Small Molecule Libraries); 214IZI85K3 (Trifluoperazine); 94F3830Q73 (Doxapram); R63VQ857OT (Amoxapine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160413
[St] Status:MEDLINE
[do] DOI:10.1128/AAC.00326-16


  9 / 535 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27038521
[Au] Autor:Haji A; Kimura S; Ohi Y
[Ad] Endereço:Laboratory of Neuropharmacology, School of Pharmacy, Aichi Gakuin University, Nagoya, Japan. Electronic address: haji@dpc.agu.ac.jp.
[Ti] Título:Reversal of morphine-induced respiratory depression by doxapram in anesthetized rats.
[So] Source:Eur J Pharmacol;780:209-15, 2016 Jun 05.
[Is] ISSN:1879-0712
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The present study was undertaken to investigate whether doxapram, a blocker of tandem pore K(+) (TASK-1/-3) channels, is a useful tool for recovery from morphine-induced ventilatory disturbances. Spontaneous ventilation and the hind leg withdrawal response against noxious thermal stimulation were recorded simultaneously in anesthetized rats. Morphine (1.0mg/kg, i.v.) decreased the minute volume resulting from depression of the ventilatory rate and tracheal airflow. Concomitantly, it prolonged the latency of withdrawal response against the thermal stimulation. Subsequent intravenous injection of doxapram recovered the morphine-induced ventilatory depression. This effect of doxapram declined rapidly after a single injection (1.0-3.0mg/kg, i.v.) but persisted with a continuous infusion (0.33mg/kg/min). Neither single injection nor continuous infusion of doxapram had any detectable effect on the analgesic potency of morphine. The central respiratory activity was recorded from the phrenic nerve in anesthetized, vagotomized, paralyzed and artificially ventilated rats. Morphine (3.0mg/kg, i.v.) induced respiratory depression, characterized by a prolonged plateau-like inspiratory discharge (apneustic discharge) in the phrenic nerve. Doxapram (10mg/kg, i.v.) restored the morphine-induced apneustic discharge to an augmenting inspiratory discharge. This study demonstrated that doxapram counteracted morphine-induced respiratory depression by stimulating the central respiratory network without compromising morphine antinociception. These results support the clinical use of doxapram for amelioration of ventilatory disturbances in patients treated with opioids.
[Mh] Termos MeSH primário: Doxapram/farmacologia
Morfina/efeitos adversos
Insuficiência Respiratória/induzido quimicamente
Insuficiência Respiratória/tratamento farmacológico
[Mh] Termos MeSH secundário: Anestesia
Animais
Masculino
Nervo Frênico/efeitos dos fármacos
Nervo Frênico/fisiopatologia
Ratos
Ratos Wistar
Insuficiência Respiratória/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
76I7G6D29C (Morphine); 94F3830Q73 (Doxapram)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170306
[Lr] Data última revisão:
170306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160404
[St] Status:MEDLINE


  10 / 535 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
[PMID]:27025814
[Au] Autor:Horsmon MS; Vincelli NM; Taylor JT; Kristovich RL
[Ad] Endereço:US Army Edgewood Chemical Biological Center, Gunpowder, Maryland, USA. michael.s.horsmon.civ@mail.mil.
[Ti] Título:An Impedance-Based Model for the Assessment of Cardiopulmonary Function in Rabbits.
[So] Source:J Am Assoc Lab Anim Sci;55(2):213-20, 2016 Mar.
[Is] ISSN:1559-6109
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Improving the quality of physiologic data collected from research animals is most easily accomplished by collecting as much information as possible from a single subject, thereby reducing animal use and error associated with satellite groups. We investigated the feasibility of using a large-animal implantable telemetry device in New Zealand white rabbits (n = 6). The first task was to develop an implantation technique that yielded calibrated tidal volume (Vt) measurements that were within 10% of those obtained simultaneously from a pneumotachograph, a low-noise electrocardiogram, and stable blood pressure. The second task was to challenge implanted rabbits with the respiratory stimulant doxapram to assess linearity of the calibration across a range of Vt. Of the 3 electrode placements attempted, only one resulted in calibrations consistently below 10% error. Optimal electrode placement resulted in calibrated Vt measurements within 1.7% ± 0.3% of those obtained from a pneumotachograph during normal tidal breathing, 7.3% ± 0.7% of those after saline injection, and 6.0% ± 0.5% of those after doxapram injection. The Vt range was 9 to 15 mL for normal tidal breathing and saline injection and 25 to 30 mL after doxapram injection. Increases in mean arterial pressure of 25.0 ± 6.82 mm Hg and decreases in heart rate of 56.3 ± 6.82 bpm were associated with doxapram injection only. Our findings represent the first time that multiple cardiopulmonary endpoints have been assessed by telemetry in conscious, restrained rabbits. Whether animal position affects calibration accuracy warrants investigation.
[Mh] Termos MeSH primário: Coelhos/fisiologia
Testes de Função Respiratória/veterinária
Telemetria/veterinária
[Mh] Termos MeSH secundário: Animais
Doxapram/administração & dosagem
Impedância Elétrica
Eletrocardiografia
Frequência Cardíaca/efeitos dos fármacos
Masculino
Testes de Função Respiratória/métodos
Fármacos do Sistema Respiratório/administração & dosagem
Telemetria/métodos
Volume de Ventilação Pulmonar
Testes de Toxicidade
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
[Nm] Nome de substância:
0 (Respiratory System Agents); 94F3830Q73 (Doxapram)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160331
[St] Status:MEDLINE



página 1 de 54 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde